CALT News and Press, Calliditas Therapeutics AB From 11/09/20

SHANGHAI, China, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, ...

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020 , Calliditas announced positive topline result...

Calliditas Therapeutics (CALT) announces positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, investigating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The analysis included 199 patients. The trial met its primary o...

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced p...

Calliditas closes acquisition of a controlling interest in Genkyotex SA PR Newswire STOCKHOLM, Nov. 3, 2020 STOCKHOLM , Nov. 3, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the clo...

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 PR Newswire STOCKHOLM, Oct. 19, 2020 STOCKHOLM , Oct. 19, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced upcoming presentations concerning Ne...

The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 PR Newswire STOCKHOLM, Oct. 1, 2020 STOCKHOLM , Oct. 1, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas")...

STOCKHOLM , Sept. 8, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced that the first patient in China has been randomized into confirmatory part of the NefIgArd Phase 3 trial by its partner, Everest Medicines. Following IND approval by the NMPA i...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . Economic reports in the week ahead Investors will have their eyes on economic reports covering construction spending, manufacturing a...

Mallinckrodt reports BLA submission for StrataGraft, fuels merger speculation Mallinckrodt ( MNK ) stock moved up as the market responded to merger rumors for the company. While the name of the likely acquirer is kept under covers, the rumors have helped the company stock, which has seen...